AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 05-13 09:30:00 美东时间
0.2833
-0.024
-7.93%
華盛通- 最 高0.3128
- 今 開0.2856
- 成交量 34.99万股
- 最 低 0.2709
- 昨 收 0.3077
- 總市值 230.83万
- 52周最高 20.3297
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.2709
- 委 比 86.92%
- 總股本 814.78万
- 歷史最高 20.3297
- 量 比 0.33
- 振 幅 13.62%
- 歷史最低 0.2709
- 每 手 1
- 風險率 2.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Announces Final Primary Endpoint Report On Objective Response Rate Data From Phase 2 Trial Evaluating Ampligen, With Topline Results Indicating 50% Objective Response Rate, Including 21% Complete Responses
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ("UPMC") Phase 2 clinical trial –
05-07 20:26
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agilon Health (NYSE:AGL) stock increased by 22.1% to $34.0 during Wedn...
05-07 05:03
AIM ImmunoTech Provides Routine Update on Annual Filings
AIM ImmunoTech Inc. (NYSE American: AIM) announced that its audited financial statements for the fiscal year ended December 31, 2025, included an audit report with a going concern emphasis of matter. The company remains confident in its ability to secure funding due to promising results from its lead drug, Ampligen, in treating late-stage pancreatic cancer. AIM recently reported positive progress in the Phase 2 DURIPANC study combining Ampligen w...
04-13 22:00
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top analysts changed outlook on top names. For complete view of all rating changes, see analyst ratings page. See others' views on stocks.
04-10 19:43
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.
04-10 17:41
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
What's Going On With AIM ImmunoTech Stock Friday?
AIM ImmunoTech (AMEX: AIM) sees bullish momentum after final patent approval in Japan for its Ampligen-based oncology treatments.
03-20 23:07
Why Is AIM ImmunoTech Stock Gaining Today?
AIM ImmunoTech stock surges after Japan fully approved a patent covering Ampligen with checkpoint inhibitors, strengthening its cancer-treatment IP portfolio.
03-19 00:08
AIM ImmunoTech Secures Full Japanese Patent For Ampligen Use With Checkpoint Inhibitors In Cancer Treatment
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in
03-18 20:38
